Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017 Summary Leading business intelligence provider GBI Research has released its latest research report, "Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017", which provides insight about immunomodulators sales forecasts until 2017.I Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market. GBI Research analysis estimated the global immunomodulators market to be valued at $145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between 2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017, to reach $259.3 billion in 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts. GBI Research analysis found the R&D pipeline for the immunomodulators market to be strong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity for immunomodulators will remain active for at least next four to five years. Scope Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines). Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017. Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes Key drivers and restraints that have had significant impact on the market. Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly. Reasons to buy Build effective strategies to launch pipeline products, by identifying potential geographies. Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps. Develop key strategic initiatives by studying the key strategies of the top competitors. Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth. Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with improved efficacy and safety profiles.

Additional Information

Immunosuppressants holds a 64% Market Share of the Immunomodulators Market with More Products in the Pipeline than Immunostimulants

Immunosuppressants generated revenues of $92.2 billion in 2010 while immunostimulants generated revenues of $53.7 billion. There are more classes of immunosuppressants than immunostimulants because it is difficult to boost the cells of the immune system as they all respond to antigens in different ways. The immunostimulants market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 10.5% and the immunosuppressants market is forecast to grow at a CAGR of 7.3%, although there are more products in the pipeline for immunosuppressants. Immunostimulatory Monoclonal Antibodies (mAbs) such as cancer antibodies and vaccines will contribute most to the growth of the markets as there is a great deal of scope for these classes in the oncology market, valued at $60.5 billion in 2010.

Antimetabolic Drugs Generated the Highest Revenues of all Classes of Immunomodulators

Antiproliferative and antimetabolic drugs generated revenues of approximately $33.2 billion in 2010. However, with the gradual approval of mAbs as first-line treatment, antiproliferative and antimetabolic drugs will grow at a comparatively slow rate. Conventional therapy, namely chemotherapy, has a long history of poor safety profiles due to systemic action characteristics, which means its often fails to impart the desired effect at the site of action. Cancer is better managed with personalized oncological treatments such as measuring erbB2 (erythroblastic leukemia viral oncogene homolog 2) and EGFR (Epidermal Growth Factor Receptor) proteins in breast, lung and colorectal cancer patients before selecting suitable treatments. Herceptin is used in the treatment of women with breast cancer in which HER2 (Human Epidermal growth factor Receptor 2) protein is overexpressed.

Antibodies Market Forecast to show Highest Growth Rate of all Classes of Immunomodulators

Antibodies were the fastest growing segment in the global immunomodulators market in 2010. The global antibodies market was worth $51.8 billion in 2010, comprising mAbs and fusion proteins. Antibodies are used in a range of oncology indications and autoimmune diseases. In 2010, immunostimulating antibodies generated revenues of $23 billion while immunosuppressive antibodies generated $28.8 billion. MAbs are gradually moving into the treatment of Central Nervous System (CNS) disorders such as Alzheimer’s disease and metabolic disorders such as diabetes. The first therapeutic mAb approved by the Food and Drug Administration (FDA) was Muromonab-CD3 (trade name Orthoclone OKT3), a murine IgG2a CD3 specific transplant rejection drug, also known as muromonab. It was approved in 1986 and was used in steroid-resistant solid organ transplant recipients. Since the launch of Orthoclone OKT3 in 1992, 30 mAbs have been launched globally. Of these, three have been discontinued due to safety issues. Successful mAbs such as rituxan, avastin and remicade have received regulatory approvals for multiple indications, further increasing the patient base.